3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Gastrointestinal
1
Conditions
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
7
Neoplasms
4
Precursor Cell Lymphoblastic Leukemia-Lymphoma
3
Leukemia
3
Carcinoma, Non-Small-Cell Lung
3
Neoplasms by Histologic Type
2
Myeloproliferative Disorders
2
Leukemia, Myeloid, Acute
2
Leukemia, Myeloid
2
Hematologic Diseases
2
Bone Marrow Diseases
2
Small Cell Lung Carcinoma
1
Piebaldism
1
Malignant Hepatobiliary Neoplasm
1
Lymphoproliferative Disorders
1
Lymphatic Diseases
1
Lung Neoplasms
1
Leukemia, Myeloid, Chronic-Phase
1
Immunoproliferative Disorders
1
Immune System Diseases
1
Hematologic Neoplasms
1
Glioblastoma
1
Gastrointestinal Stromal Tumors
1
Gastrointestinal Neoplasms
1
Adenocarcinoma of Lung
1
Interventions
Imatinib Mesylate
41
Sunitinib
17
nilotinib
12
regorafenib
10
ripretinib
6
avapritinib
6
Leucovorin
3
Ipilimumab
3
Gemcitabine
3
Dasatinib
3
CTLA-4 Antigen
3
4-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one
3
pexidartinib
2
Paclitaxel
2
Oxaliplatin
2
Midazolam
2
Irinotecan
2
Fluorouracil
2
Floxuridine
2
Erlotinib Hydrochloride
2
Docetaxel
2
Cisplatin
2
Carboplatin
2
Capecitabine
2
Biopsy, Fine-Needle
2
Bevacizumab
2
vatalanib
1
umbralisib
1
trametinib
1
tinostamustine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Gastrointestinal Stromal Tumors
×
ponatinib
×
Clear all
NCT01874665
2018-05-18
GIST
Takeda
Phase 2
Completed
45 enrolled
21 charts